The healthcare unit of Tata Group, Tata Medical and Diagnostics is in its early talks with the Moderna Inc to launch its Covid-19 vaccine for the Indian consumers. As India mandates the necessary local trials for any vaccine to get approval for the Indian market, it is likely that Tata will join hands with CSIR to conduct the clinical trials.
The American developed vaccine is seen as a good option for the poor countries, which lacks storage infrastructure, as it can be stored in normal fridge temperatures unlike the Pfizer, which requires minus 70 degrees.
Having proved its efficacy of 94.1% with no serious health concerns in the month of November, the shot received its approval for use in the United States in December. Recently it has received the go-ahead permission in Europe too.